BOSTON, March 14, 2022 /PRNewswire/ — Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration…Original Article
FDA Approves Adlarity (donepezil transdermal system) for Treatment of Patients with Alzheimer’s Disease
